GlassScriptPhysician profile
James B Winston
NPI 1124111893
$6,657.91
in general payments reported to CMS, 2019-2025
23 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,956 · 2020: $445 · 2021: $404 · 2022: $145 · 2023: $253 · 2024: $2,979 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,640 · Food and Beverage: $627 · Education: $390 · Travel and Lodging: $49.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,640.00 |
| Food and Beverage | $627.33 |
| Education | $390.47 |
| Travel and Lodging | $49.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $2,725.21 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $837.02 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $540.16 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $331.70 | 2019-2024 | Rexulti |
| Treace Medical Concepts, INC. | $303.13 | 2021 | |
| Shire North American Group INC | $302.51 | 2019 | |
| Lundbeck LLC | $217.81 | 2019-2020 | |
| Harmony Biosciences LLC | $211.33 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.72 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $176.21 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $158.59 | 2019 | |
| Allergan, INC. | $99.46 | 2019-2020 | |
| Adlon Therapeutics L.P. | $84.81 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $79.32 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $76.22 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $75.21 | 2019-2020 | |
| Neos Therapeutics, LP | $72.32 | 2019-2020 | |
| Almatica Pharma LLC | $45.29 | 2024-2025 | Loreev Xr |
| Bausch Health US, LLC | $38.19 | 2019 | |
| Vertical Pharmaceuticals, LLC | $25.46 | 2019 | |
| Biogen, INC. | $24.81 | 2024 | Leqembi |
| Orexo US, INC. | $14.89 | 2021 | |
| Vanda Pharmaceuticals INC. | $12.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Winston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.